Ezetimibe's Common Side Effects
Ezetimibe, often sold as Zetia, primarily causes mild gastrointestinal issues like diarrhea (4-5% of users), abdominal pain (3-4%), and flatulence (2-3%). Upper respiratory infections occur in about 4%, and muscle pain (myalgia) in 3-5%. Serious effects like liver enzyme elevations or rhabdomyolysis are rare (<1%), especially when used alone.[1][2]
How Ezetimibe Compares to Statins
Statins (e.g., atorvastatin/Lipitor, rosuvastatin/Crestor) lower LDL more effectively (30-60% vs. ezetimibe's 15-20%) but have higher rates of muscle-related side effects: myalgia in 5-10%, with severe rhabdomyolysis in 0.01-0.1%. New-onset diabetes risk rises 9-12% with high-intensity statins. Ezetimibe shows lower muscle and diabetes risks, making it a statin alternative or add-on. Head-to-head trials like IMPROVE-IT confirm ezetimibe's better tolerability when combined with simvastatin.[1][3][4]
Comparison to PCSK9 Inhibitors
PCSK9 drugs like evolocumab (Repatha) and alirocumab (Praluent) cut LDL by 50-70% but involve injection-site reactions (5-10%), flu-like symptoms (7-8%), and rare neurocognitive effects. Ezetimibe, taken orally once daily, avoids these and has fewer overall discontinuations (3-5% vs. 7-12% for PCSK9s).[2][5]
Vs. Bempedoic Acid and Bempeg
Bempedoic acid (Nexletol), which activates in the liver unlike statins, reports higher gout (1-3%), uric acid increases, and tendon ruptures (<1%). Its myalgia rate matches statins (4-6%), but ezetimibe edges out with fewer metabolic effects. Combo bempedoic-ezetimibe (Nexlizet) maintains ezetimibe's low profile.[1][6]
Vs. Fibrates and Bile Acid Sequestrants
Fibrates (e.g., fenofibrate) raise gallstone and creatinine risks (2-5%), while bile acid binders like colesevelam cause constipation (10-15%) and bloating. Ezetimibe has a cleaner GI profile and no such systemic issues, though less potent for triglycerides.[2]
Patient Considerations and Discontinuation Rates
Across classes, ezetimibe's discontinuation rate is lowest at 3-6%, vs. 10-15% for statins due to muscle pain. It's preferred for statin-intolerant patients, with trials showing 80-90% tolerate it long-term. No major drug interactions beyond bile acid sequestrants; monitor liver enzymes with statins.[3][4]
Sources
[1]: FDA Label - Zetia (ezetimibe)
[2]: UpToDate - Ezetimibe overview
[3]: IMPROVE-IT Trial - NEJM
[4]: Statins Adverse Effects - Lancet
[5]: FOURIER Trial - PCSK9s - NEJM
[6]: FDA Label - Nexletol (bempedoic acid)